Clinical Pharmacokinetics

, Volume 44, Issue 5, pp 495–507

Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients

  • Hugh Wiltshire
  • Sarapee Hirankarn
  • Colm Farrell
  • Carlos Paya
  • Mark D. Pescovitz
  • Atul Humar
  • Edward Dominguez
  • Kenneth Washburn
  • Emily Blumberg
  • Barbara Alexander
  • Richard Freeman
  • Nigel Heaton
Original Research Article

DOI: 10.2165/00003088-200544050-00003

Cite this article as:
Wiltshire, H., Hirankarn, S., Farrell, C. et al. Clin Pharmacokinet (2005) 44: 495. doi:10.2165/00003088-200544050-00003

Abstract

Background

Valganciclovir (Valcyte/sR) has recently been approved for the prevention of cytomegalovirus (CMV) disease in high-risk (CMV donor positive [D+1/recipient negative [R−]) solid organ transplant (SOT) recipients. Large-scale studies describing the pharmacokinetics of valganciclovir in SOT recipients are lacking. A recent randomised, double-blind study of valganciclovir in 364 D+/R− (intent-to-treat population) SOT recipients provided valuable data on which a population pharmacokinetic analysis was performed.

Methods

The pharmacokinetics of ganciclovir from oral ganciclovir (Cymevene®, lOOOmg three times daily) and from valganciclovir (900mg once daily) were described with plasma levels from 240 patients (1181 datapoints describing 449 pharmacokinetic profiles) using nonlinear mixed-effects modelling (NONMEM) software. A two-compartment pharmacokinetic model with separate absorption/metabolism and absorption parameters for valganciclovir and ganciclovir, respectively, was developed.

Results

Exposure to ganciclovir from valganciclovir averaged 1.65-fold greater than that from oral ganciclovir (95% CI 1.58, 1.81); respective daily area under the plasma concentration-time curve values were 46.3 + 15.2 μg · h/mL and 28.0 ± 10.9 μg · h/mL. The relative systemic exposure of ganciclovir was approximately 8-fold higher from valganciclovir than oral ganciclovir. Exposure to ganciclovir from valganciclovir was similar among liver, heart and kidney transplant recipients (46.0 + 16.1, 40.2 + 11.8 and 48.2 + 14.6 μg · h/mL, respectively). Adherence to the prescribed dosing regimens, which were reduced for renal impairment, gave consistent exposure to ganciclovir.

Conclusion

Oral valganciclovir produces exposures of ganciclovir exceeding those attained with oral ganciclovir, but in line with those reported after standard intravenous administration of ganciclovir. This indicates that oral valganciclovir is suitable in circumstances requiring prophylactic use of ganciclovir and allows for more convenient management of patients at risk of CMV disease.

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Hugh Wiltshire
    • 1
  • Sarapee Hirankarn
    • 2
  • Colm Farrell
    • 2
  • Carlos Paya
    • 3
  • Mark D. Pescovitz
    • 4
  • Atul Humar
    • 5
  • Edward Dominguez
    • 6
  • Kenneth Washburn
    • 7
  • Emily Blumberg
    • 8
  • Barbara Alexander
    • 9
  • Richard Freeman
    • 10
  • Nigel Heaton
    • 11
  1. 1.Roche Products LtdWelwyn Garden CityUK
  2. 2.GloboMax — a division of ICON plcMarlowUK
  3. 3.Mayo ClinicRochesterUSA
  4. 4.Departments of Surgery/Microbiology/ImmunologyIndiana UniversityIndianapolisUSA
  5. 5.Toronto General HospitalTorontoCanada
  6. 6.University of Nebraska Medical CenterOmahaUSA
  7. 7.University of Texas Health Science CenterSan AntonioUSA
  8. 8.Hospital of the University of PennsylvaniaPhiladelphiaUSA
  9. 9.Duke University Medical CenterDurhamUSA
  10. 10.New England Medical CenterBostonUSA
  11. 11.King’s CollegeLondonUK